nodes	percent_of_prediction	percent_of_DWPC	metapath
Levofloxacin—SLC22A6—Captopril—systemic scleroderma	0.118	0.207	CbGbCtD
Levofloxacin—CYP1A2—Pentoxifylline—systemic scleroderma	0.0804	0.141	CbGbCtD
Levofloxacin—CYP1A2—Leflunomide—systemic scleroderma	0.0767	0.134	CbGbCtD
Levofloxacin—ABCB1—Lisinopril—systemic scleroderma	0.0703	0.123	CbGbCtD
Levofloxacin—ABCB1—Captopril—systemic scleroderma	0.0526	0.0921	CbGbCtD
Levofloxacin—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0414	0.0725	CbGbCtD
Levofloxacin—SLC22A6—Methotrexate—systemic scleroderma	0.0373	0.0653	CbGbCtD
Levofloxacin—ABCB1—Prednisone—systemic scleroderma	0.0331	0.058	CbGbCtD
Levofloxacin—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0248	0.0435	CbGbCtD
Levofloxacin—CYP3A4—Prednisone—systemic scleroderma	0.0198	0.0347	CbGbCtD
Levofloxacin—ABCB1—Methotrexate—systemic scleroderma	0.0166	0.0291	CbGbCtD
Levofloxacin—TOP2A—Methyltestosterone—Prednisone—systemic scleroderma	0.000621	1	CbGdCrCtD
Levofloxacin—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000123	0.000287	CcSEcCtD
Levofloxacin—Hypersensitivity—Azathioprine—systemic scleroderma	0.000123	0.000286	CcSEcCtD
Levofloxacin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000123	0.000286	CcSEcCtD
Levofloxacin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000286	CcSEcCtD
Levofloxacin—Insomnia—Lisinopril—systemic scleroderma	0.000122	0.000285	CcSEcCtD
Levofloxacin—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000285	CcSEcCtD
Levofloxacin—Paraesthesia—Lisinopril—systemic scleroderma	0.000121	0.000283	CcSEcCtD
Levofloxacin—Vomiting—Captopril—systemic scleroderma	0.000121	0.000283	CcSEcCtD
Levofloxacin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000282	CcSEcCtD
Levofloxacin—Dyspnoea—Lisinopril—systemic scleroderma	0.00012	0.000281	CcSEcCtD
Levofloxacin—Rash—Captopril—systemic scleroderma	0.00012	0.000281	CcSEcCtD
Levofloxacin—Dermatitis—Captopril—systemic scleroderma	0.00012	0.00028	CcSEcCtD
Levofloxacin—Somnolence—Lisinopril—systemic scleroderma	0.00012	0.00028	CcSEcCtD
Levofloxacin—Headache—Captopril—systemic scleroderma	0.000119	0.000279	CcSEcCtD
Levofloxacin—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000279	CcSEcCtD
Levofloxacin—Dyspepsia—Lisinopril—systemic scleroderma	0.000119	0.000278	CcSEcCtD
Levofloxacin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000118	0.000277	CcSEcCtD
Levofloxacin—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000118	0.000277	CcSEcCtD
Levofloxacin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000276	CcSEcCtD
Levofloxacin—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000276	CcSEcCtD
Levofloxacin—Asthma—Methotrexate—systemic scleroderma	0.000118	0.000275	CcSEcCtD
Levofloxacin—Infection—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000274	CcSEcCtD
Levofloxacin—Decreased appetite—Lisinopril—systemic scleroderma	0.000117	0.000274	CcSEcCtD
Levofloxacin—Eosinophilia—Methotrexate—systemic scleroderma	0.000117	0.000272	CcSEcCtD
Levofloxacin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000117	0.000272	CcSEcCtD
Levofloxacin—Fatigue—Lisinopril—systemic scleroderma	0.000116	0.000272	CcSEcCtD
Levofloxacin—Shock—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000272	CcSEcCtD
Levofloxacin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000271	CcSEcCtD
Levofloxacin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000116	0.00027	CcSEcCtD
Levofloxacin—Hypersensitivity—Leflunomide—systemic scleroderma	0.000116	0.00027	CcSEcCtD
Levofloxacin—Pancreatitis—Methotrexate—systemic scleroderma	0.000116	0.00027	CcSEcCtD
Levofloxacin—Constipation—Lisinopril—systemic scleroderma	0.000115	0.00027	CcSEcCtD
Levofloxacin—Pain—Lisinopril—systemic scleroderma	0.000115	0.00027	CcSEcCtD
Levofloxacin—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000115	0.00027	CcSEcCtD
Levofloxacin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000268	CcSEcCtD
Levofloxacin—Bradycardia—Prednisone—systemic scleroderma	0.000115	0.000268	CcSEcCtD
Levofloxacin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000267	CcSEcCtD
Levofloxacin—Diarrhoea—Azathioprine—systemic scleroderma	0.000114	0.000266	CcSEcCtD
Levofloxacin—Haemoglobin—Prednisone—systemic scleroderma	0.000113	0.000265	CcSEcCtD
Levofloxacin—Nausea—Captopril—systemic scleroderma	0.000113	0.000264	CcSEcCtD
Levofloxacin—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000113	0.000264	CcSEcCtD
Levofloxacin—Haemorrhage—Prednisone—systemic scleroderma	0.000113	0.000264	CcSEcCtD
Levofloxacin—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000113	0.000263	CcSEcCtD
Levofloxacin—Asthenia—Leflunomide—systemic scleroderma	0.000113	0.000263	CcSEcCtD
Levofloxacin—Hallucination—Prednisone—systemic scleroderma	0.000112	0.000262	CcSEcCtD
Levofloxacin—Pancytopenia—Methotrexate—systemic scleroderma	0.000112	0.000261	CcSEcCtD
Levofloxacin—Feeling abnormal—Lisinopril—systemic scleroderma	0.000111	0.00026	CcSEcCtD
Levofloxacin—Pruritus—Leflunomide—systemic scleroderma	0.000111	0.00026	CcSEcCtD
Levofloxacin—Connective tissue disorder—Prednisone—systemic scleroderma	0.000111	0.000259	CcSEcCtD
Levofloxacin—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000258	CcSEcCtD
Levofloxacin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00011	0.000258	CcSEcCtD
Levofloxacin—Neutropenia—Methotrexate—systemic scleroderma	0.00011	0.000257	CcSEcCtD
Levofloxacin—Dysuria—Methotrexate—systemic scleroderma	0.00011	0.000257	CcSEcCtD
Levofloxacin—Dizziness—Azathioprine—systemic scleroderma	0.00011	0.000257	CcSEcCtD
Levofloxacin—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000109	0.000256	CcSEcCtD
Levofloxacin—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000108	0.000253	CcSEcCtD
Levofloxacin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000252	CcSEcCtD
Levofloxacin—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000108	0.000251	CcSEcCtD
Levofloxacin—Asthenia—Mycophenolic acid—systemic scleroderma	0.000108	0.000251	CcSEcCtD
Levofloxacin—Diarrhoea—Leflunomide—systemic scleroderma	0.000107	0.000251	CcSEcCtD
Levofloxacin—Urticaria—Lisinopril—systemic scleroderma	0.000107	0.00025	CcSEcCtD
Levofloxacin—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000107	0.00025	CcSEcCtD
Levofloxacin—Abdominal pain—Lisinopril—systemic scleroderma	0.000107	0.000249	CcSEcCtD
Levofloxacin—Body temperature increased—Lisinopril—systemic scleroderma	0.000107	0.000249	CcSEcCtD
Levofloxacin—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000248	CcSEcCtD
Levofloxacin—Pruritus—Mycophenolic acid—systemic scleroderma	0.000106	0.000248	CcSEcCtD
Levofloxacin—Vomiting—Azathioprine—systemic scleroderma	0.000106	0.000247	CcSEcCtD
Levofloxacin—Pneumonia—Methotrexate—systemic scleroderma	0.000106	0.000247	CcSEcCtD
Levofloxacin—Eye disorder—Prednisone—systemic scleroderma	0.000105	0.000246	CcSEcCtD
Levofloxacin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000246	CcSEcCtD
Levofloxacin—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000246	CcSEcCtD
Levofloxacin—Infestation—Methotrexate—systemic scleroderma	0.000105	0.000245	CcSEcCtD
Levofloxacin—Infestation NOS—Methotrexate—systemic scleroderma	0.000105	0.000245	CcSEcCtD
Levofloxacin—Drowsiness—Methotrexate—systemic scleroderma	0.000105	0.000245	CcSEcCtD
Levofloxacin—Rash—Azathioprine—systemic scleroderma	0.000105	0.000245	CcSEcCtD
Levofloxacin—Dermatitis—Azathioprine—systemic scleroderma	0.000105	0.000245	CcSEcCtD
Levofloxacin—Flushing—Prednisone—systemic scleroderma	0.000105	0.000245	CcSEcCtD
Levofloxacin—Headache—Azathioprine—systemic scleroderma	0.000104	0.000243	CcSEcCtD
Levofloxacin—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000104	0.000243	CcSEcCtD
Levofloxacin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000243	CcSEcCtD
Levofloxacin—Dizziness—Leflunomide—systemic scleroderma	0.000104	0.000243	CcSEcCtD
Levofloxacin—Renal failure—Methotrexate—systemic scleroderma	0.000103	0.000241	CcSEcCtD
Levofloxacin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000103	0.00024	CcSEcCtD
Levofloxacin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000103	0.00024	CcSEcCtD
Levofloxacin—Stomatitis—Methotrexate—systemic scleroderma	0.000102	0.000239	CcSEcCtD
Levofloxacin—Angiopathy—Prednisone—systemic scleroderma	0.000102	0.000239	CcSEcCtD
Levofloxacin—Conjunctivitis—Methotrexate—systemic scleroderma	0.000102	0.000239	CcSEcCtD
Levofloxacin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000239	CcSEcCtD
Levofloxacin—Immune system disorder—Prednisone—systemic scleroderma	0.000102	0.000238	CcSEcCtD
Levofloxacin—Pain—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000236	CcSEcCtD
Levofloxacin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000236	CcSEcCtD
Levofloxacin—Arrhythmia—Prednisone—systemic scleroderma	0.000101	0.000235	CcSEcCtD
Levofloxacin—Haematuria—Methotrexate—systemic scleroderma	0.0001	0.000234	CcSEcCtD
Levofloxacin—Vomiting—Leflunomide—systemic scleroderma	9.99e-05	0.000233	CcSEcCtD
Levofloxacin—Alopecia—Prednisone—systemic scleroderma	9.97e-05	0.000233	CcSEcCtD
Levofloxacin—Hypersensitivity—Lisinopril—systemic scleroderma	9.94e-05	0.000232	CcSEcCtD
Levofloxacin—Hepatobiliary disease—Methotrexate—systemic scleroderma	9.93e-05	0.000232	CcSEcCtD
Levofloxacin—Dizziness—Mycophenolic acid—systemic scleroderma	9.91e-05	0.000231	CcSEcCtD
Levofloxacin—Epistaxis—Methotrexate—systemic scleroderma	9.91e-05	0.000231	CcSEcCtD
Levofloxacin—Rash—Leflunomide—systemic scleroderma	9.9e-05	0.000231	CcSEcCtD
Levofloxacin—Dermatitis—Leflunomide—systemic scleroderma	9.89e-05	0.000231	CcSEcCtD
Levofloxacin—Mental disorder—Prednisone—systemic scleroderma	9.88e-05	0.000231	CcSEcCtD
Levofloxacin—Nausea—Azathioprine—systemic scleroderma	9.88e-05	0.000231	CcSEcCtD
Levofloxacin—Headache—Leflunomide—systemic scleroderma	9.84e-05	0.00023	CcSEcCtD
Levofloxacin—Malnutrition—Prednisone—systemic scleroderma	9.82e-05	0.000229	CcSEcCtD
Levofloxacin—Erythema—Prednisone—systemic scleroderma	9.82e-05	0.000229	CcSEcCtD
Levofloxacin—Agranulocytosis—Methotrexate—systemic scleroderma	9.8e-05	0.000229	CcSEcCtD
Levofloxacin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	9.74e-05	0.000228	CcSEcCtD
Levofloxacin—Asthenia—Lisinopril—systemic scleroderma	9.68e-05	0.000226	CcSEcCtD
Levofloxacin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	9.67e-05	0.000226	CcSEcCtD
Levofloxacin—Pruritus—Lisinopril—systemic scleroderma	9.55e-05	0.000223	CcSEcCtD
Levofloxacin—Vomiting—Mycophenolic acid—systemic scleroderma	9.53e-05	0.000223	CcSEcCtD
Levofloxacin—Haemoglobin—Methotrexate—systemic scleroderma	9.48e-05	0.000221	CcSEcCtD
Levofloxacin—Rash—Mycophenolic acid—systemic scleroderma	9.45e-05	0.000221	CcSEcCtD
Levofloxacin—Dermatitis—Mycophenolic acid—systemic scleroderma	9.44e-05	0.000221	CcSEcCtD
Levofloxacin—Hepatitis—Methotrexate—systemic scleroderma	9.43e-05	0.00022	CcSEcCtD
Levofloxacin—Haemorrhage—Methotrexate—systemic scleroderma	9.43e-05	0.00022	CcSEcCtD
Levofloxacin—Urticaria—Mycophenolate mofetil—systemic scleroderma	9.39e-05	0.000219	CcSEcCtD
Levofloxacin—Headache—Mycophenolic acid—systemic scleroderma	9.39e-05	0.000219	CcSEcCtD
Levofloxacin—Pharyngitis—Methotrexate—systemic scleroderma	9.36e-05	0.000219	CcSEcCtD
Levofloxacin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	9.35e-05	0.000218	CcSEcCtD
Levofloxacin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	9.35e-05	0.000218	CcSEcCtD
Levofloxacin—Nausea—Leflunomide—systemic scleroderma	9.33e-05	0.000218	CcSEcCtD
Levofloxacin—Urinary tract disorder—Methotrexate—systemic scleroderma	9.31e-05	0.000218	CcSEcCtD
Levofloxacin—Vision blurred—Prednisone—systemic scleroderma	9.26e-05	0.000216	CcSEcCtD
Levofloxacin—Urethral disorder—Methotrexate—systemic scleroderma	9.24e-05	0.000216	CcSEcCtD
Levofloxacin—Diarrhoea—Lisinopril—systemic scleroderma	9.23e-05	0.000216	CcSEcCtD
Levofloxacin—Ill-defined disorder—Prednisone—systemic scleroderma	9.11e-05	0.000213	CcSEcCtD
Levofloxacin—Visual impairment—Methotrexate—systemic scleroderma	9.09e-05	0.000212	CcSEcCtD
Levofloxacin—Anaemia—Prednisone—systemic scleroderma	9.08e-05	0.000212	CcSEcCtD
Levofloxacin—Agitation—Prednisone—systemic scleroderma	9.03e-05	0.000211	CcSEcCtD
Levofloxacin—Angioedema—Prednisone—systemic scleroderma	8.97e-05	0.00021	CcSEcCtD
Levofloxacin—Dizziness—Lisinopril—systemic scleroderma	8.93e-05	0.000209	CcSEcCtD
Levofloxacin—Erythema multiforme—Methotrexate—systemic scleroderma	8.92e-05	0.000208	CcSEcCtD
Levofloxacin—Nausea—Mycophenolic acid—systemic scleroderma	8.9e-05	0.000208	CcSEcCtD
Levofloxacin—Malaise—Prednisone—systemic scleroderma	8.86e-05	0.000207	CcSEcCtD
Levofloxacin—Vertigo—Prednisone—systemic scleroderma	8.82e-05	0.000206	CcSEcCtD
Levofloxacin—Eye disorder—Methotrexate—systemic scleroderma	8.81e-05	0.000206	CcSEcCtD
Levofloxacin—Syncope—Prednisone—systemic scleroderma	8.81e-05	0.000206	CcSEcCtD
Levofloxacin—Tinnitus—Methotrexate—systemic scleroderma	8.79e-05	0.000205	CcSEcCtD
Levofloxacin—Cardiac disorder—Methotrexate—systemic scleroderma	8.75e-05	0.000204	CcSEcCtD
Levofloxacin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	8.71e-05	0.000204	CcSEcCtD
Levofloxacin—Loss of consciousness—Prednisone—systemic scleroderma	8.63e-05	0.000202	CcSEcCtD
Levofloxacin—Vomiting—Lisinopril—systemic scleroderma	8.58e-05	0.0002	CcSEcCtD
Levofloxacin—Angiopathy—Methotrexate—systemic scleroderma	8.56e-05	0.0002	CcSEcCtD
Levofloxacin—Immune system disorder—Methotrexate—systemic scleroderma	8.52e-05	0.000199	CcSEcCtD
Levofloxacin—Rash—Lisinopril—systemic scleroderma	8.51e-05	0.000199	CcSEcCtD
Levofloxacin—Dermatitis—Lisinopril—systemic scleroderma	8.5e-05	0.000199	CcSEcCtD
Levofloxacin—Mediastinal disorder—Methotrexate—systemic scleroderma	8.5e-05	0.000199	CcSEcCtD
Levofloxacin—Asthenia—Mycophenolate mofetil—systemic scleroderma	8.48e-05	0.000198	CcSEcCtD
Levofloxacin—Hypertension—Prednisone—systemic scleroderma	8.48e-05	0.000198	CcSEcCtD
Levofloxacin—Chills—Methotrexate—systemic scleroderma	8.46e-05	0.000198	CcSEcCtD
Levofloxacin—Headache—Lisinopril—systemic scleroderma	8.46e-05	0.000198	CcSEcCtD
Levofloxacin—Pruritus—Mycophenolate mofetil—systemic scleroderma	8.37e-05	0.000195	CcSEcCtD
Levofloxacin—Arthralgia—Prednisone—systemic scleroderma	8.36e-05	0.000195	CcSEcCtD
Levofloxacin—Myalgia—Prednisone—systemic scleroderma	8.36e-05	0.000195	CcSEcCtD
Levofloxacin—Anxiety—Prednisone—systemic scleroderma	8.33e-05	0.000195	CcSEcCtD
Levofloxacin—Alopecia—Methotrexate—systemic scleroderma	8.33e-05	0.000195	CcSEcCtD
Levofloxacin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	8.3e-05	0.000194	CcSEcCtD
Levofloxacin—Discomfort—Prednisone—systemic scleroderma	8.26e-05	0.000193	CcSEcCtD
Levofloxacin—Mental disorder—Methotrexate—systemic scleroderma	8.26e-05	0.000193	CcSEcCtD
Levofloxacin—Malnutrition—Methotrexate—systemic scleroderma	8.21e-05	0.000192	CcSEcCtD
Levofloxacin—Erythema—Methotrexate—systemic scleroderma	8.21e-05	0.000192	CcSEcCtD
Levofloxacin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	8.09e-05	0.000189	CcSEcCtD
Levofloxacin—Dysgeusia—Methotrexate—systemic scleroderma	8.04e-05	0.000188	CcSEcCtD
Levofloxacin—Nausea—Lisinopril—systemic scleroderma	8.02e-05	0.000187	CcSEcCtD
Levofloxacin—Anaphylactic shock—Prednisone—systemic scleroderma	8.02e-05	0.000187	CcSEcCtD
Levofloxacin—Oedema—Prednisone—systemic scleroderma	8.02e-05	0.000187	CcSEcCtD
Levofloxacin—Infection—Prednisone—systemic scleroderma	7.96e-05	0.000186	CcSEcCtD
Levofloxacin—Back pain—Methotrexate—systemic scleroderma	7.94e-05	0.000185	CcSEcCtD
Levofloxacin—Shock—Prednisone—systemic scleroderma	7.89e-05	0.000184	CcSEcCtD
Levofloxacin—Nervous system disorder—Prednisone—systemic scleroderma	7.86e-05	0.000184	CcSEcCtD
Levofloxacin—Tachycardia—Prednisone—systemic scleroderma	7.82e-05	0.000183	CcSEcCtD
Levofloxacin—Dizziness—Mycophenolate mofetil—systemic scleroderma	7.82e-05	0.000183	CcSEcCtD
Levofloxacin—Skin disorder—Prednisone—systemic scleroderma	7.79e-05	0.000182	CcSEcCtD
Levofloxacin—Hyperhidrosis—Prednisone—systemic scleroderma	7.75e-05	0.000181	CcSEcCtD
Levofloxacin—Vision blurred—Methotrexate—systemic scleroderma	7.74e-05	0.000181	CcSEcCtD
Levofloxacin—Anorexia—Prednisone—systemic scleroderma	7.64e-05	0.000178	CcSEcCtD
Levofloxacin—Ill-defined disorder—Methotrexate—systemic scleroderma	7.62e-05	0.000178	CcSEcCtD
Levofloxacin—Anaemia—Methotrexate—systemic scleroderma	7.59e-05	0.000177	CcSEcCtD
Levofloxacin—Vomiting—Mycophenolate mofetil—systemic scleroderma	7.52e-05	0.000176	CcSEcCtD
Levofloxacin—Rash—Mycophenolate mofetil—systemic scleroderma	7.46e-05	0.000174	CcSEcCtD
Levofloxacin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	7.45e-05	0.000174	CcSEcCtD
Levofloxacin—Headache—Mycophenolate mofetil—systemic scleroderma	7.41e-05	0.000173	CcSEcCtD
Levofloxacin—Malaise—Methotrexate—systemic scleroderma	7.4e-05	0.000173	CcSEcCtD
Levofloxacin—Vertigo—Methotrexate—systemic scleroderma	7.37e-05	0.000172	CcSEcCtD
Levofloxacin—Leukopenia—Methotrexate—systemic scleroderma	7.35e-05	0.000172	CcSEcCtD
Levofloxacin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	7.3e-05	0.000171	CcSEcCtD
Levofloxacin—Insomnia—Prednisone—systemic scleroderma	7.25e-05	0.000169	CcSEcCtD
Levofloxacin—Paraesthesia—Prednisone—systemic scleroderma	7.2e-05	0.000168	CcSEcCtD
Levofloxacin—Cough—Methotrexate—systemic scleroderma	7.16e-05	0.000167	CcSEcCtD
Levofloxacin—Dyspepsia—Prednisone—systemic scleroderma	7.06e-05	0.000165	CcSEcCtD
Levofloxacin—Nausea—Mycophenolate mofetil—systemic scleroderma	7.02e-05	0.000164	CcSEcCtD
Levofloxacin—Arthralgia—Methotrexate—systemic scleroderma	6.99e-05	0.000163	CcSEcCtD
Levofloxacin—Chest pain—Methotrexate—systemic scleroderma	6.99e-05	0.000163	CcSEcCtD
Levofloxacin—Myalgia—Methotrexate—systemic scleroderma	6.99e-05	0.000163	CcSEcCtD
Levofloxacin—Decreased appetite—Prednisone—systemic scleroderma	6.97e-05	0.000163	CcSEcCtD
Levofloxacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	6.94e-05	0.000162	CcSEcCtD
Levofloxacin—Fatigue—Prednisone—systemic scleroderma	6.91e-05	0.000161	CcSEcCtD
Levofloxacin—Discomfort—Methotrexate—systemic scleroderma	6.9e-05	0.000161	CcSEcCtD
Levofloxacin—Constipation—Prednisone—systemic scleroderma	6.85e-05	0.00016	CcSEcCtD
Levofloxacin—Confusional state—Methotrexate—systemic scleroderma	6.75e-05	0.000158	CcSEcCtD
Levofloxacin—Anaphylactic shock—Methotrexate—systemic scleroderma	6.7e-05	0.000157	CcSEcCtD
Levofloxacin—Infection—Methotrexate—systemic scleroderma	6.66e-05	0.000155	CcSEcCtD
Levofloxacin—Feeling abnormal—Prednisone—systemic scleroderma	6.61e-05	0.000154	CcSEcCtD
Levofloxacin—Nervous system disorder—Methotrexate—systemic scleroderma	6.57e-05	0.000153	CcSEcCtD
Levofloxacin—Thrombocytopenia—Methotrexate—systemic scleroderma	6.56e-05	0.000153	CcSEcCtD
Levofloxacin—Gastrointestinal pain—Prednisone—systemic scleroderma	6.55e-05	0.000153	CcSEcCtD
Levofloxacin—Skin disorder—Methotrexate—systemic scleroderma	6.51e-05	0.000152	CcSEcCtD
Levofloxacin—Hyperhidrosis—Methotrexate—systemic scleroderma	6.48e-05	0.000151	CcSEcCtD
Levofloxacin—Anorexia—Methotrexate—systemic scleroderma	6.39e-05	0.000149	CcSEcCtD
Levofloxacin—Urticaria—Prednisone—systemic scleroderma	6.37e-05	0.000149	CcSEcCtD
Levofloxacin—Abdominal pain—Prednisone—systemic scleroderma	6.34e-05	0.000148	CcSEcCtD
Levofloxacin—Body temperature increased—Prednisone—systemic scleroderma	6.34e-05	0.000148	CcSEcCtD
Levofloxacin—Hypotension—Methotrexate—systemic scleroderma	6.26e-05	0.000146	CcSEcCtD
Levofloxacin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	6.1e-05	0.000143	CcSEcCtD
Levofloxacin—Insomnia—Methotrexate—systemic scleroderma	6.06e-05	0.000142	CcSEcCtD
Levofloxacin—Paraesthesia—Methotrexate—systemic scleroderma	6.02e-05	0.000141	CcSEcCtD
Levofloxacin—Dyspnoea—Methotrexate—systemic scleroderma	5.97e-05	0.00014	CcSEcCtD
Levofloxacin—Somnolence—Methotrexate—systemic scleroderma	5.96e-05	0.000139	CcSEcCtD
Levofloxacin—Hypersensitivity—Prednisone—systemic scleroderma	5.91e-05	0.000138	CcSEcCtD
Levofloxacin—Dyspepsia—Methotrexate—systemic scleroderma	5.9e-05	0.000138	CcSEcCtD
Levofloxacin—Decreased appetite—Methotrexate—systemic scleroderma	5.82e-05	0.000136	CcSEcCtD
Levofloxacin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	5.78e-05	0.000135	CcSEcCtD
Levofloxacin—Fatigue—Methotrexate—systemic scleroderma	5.78e-05	0.000135	CcSEcCtD
Levofloxacin—Asthenia—Prednisone—systemic scleroderma	5.75e-05	0.000134	CcSEcCtD
Levofloxacin—Pain—Methotrexate—systemic scleroderma	5.73e-05	0.000134	CcSEcCtD
Levofloxacin—Pruritus—Prednisone—systemic scleroderma	5.67e-05	0.000132	CcSEcCtD
Levofloxacin—Feeling abnormal—Methotrexate—systemic scleroderma	5.52e-05	0.000129	CcSEcCtD
Levofloxacin—Diarrhoea—Prednisone—systemic scleroderma	5.48e-05	0.000128	CcSEcCtD
Levofloxacin—Gastrointestinal pain—Methotrexate—systemic scleroderma	5.48e-05	0.000128	CcSEcCtD
Levofloxacin—Urticaria—Methotrexate—systemic scleroderma	5.32e-05	0.000124	CcSEcCtD
Levofloxacin—Dizziness—Prednisone—systemic scleroderma	5.3e-05	0.000124	CcSEcCtD
Levofloxacin—Body temperature increased—Methotrexate—systemic scleroderma	5.3e-05	0.000124	CcSEcCtD
Levofloxacin—Abdominal pain—Methotrexate—systemic scleroderma	5.3e-05	0.000124	CcSEcCtD
Levofloxacin—Vomiting—Prednisone—systemic scleroderma	5.1e-05	0.000119	CcSEcCtD
Levofloxacin—Rash—Prednisone—systemic scleroderma	5.05e-05	0.000118	CcSEcCtD
Levofloxacin—Dermatitis—Prednisone—systemic scleroderma	5.05e-05	0.000118	CcSEcCtD
Levofloxacin—Headache—Prednisone—systemic scleroderma	5.02e-05	0.000117	CcSEcCtD
Levofloxacin—Hypersensitivity—Methotrexate—systemic scleroderma	4.94e-05	0.000115	CcSEcCtD
Levofloxacin—Asthenia—Methotrexate—systemic scleroderma	4.81e-05	0.000112	CcSEcCtD
Levofloxacin—Nausea—Prednisone—systemic scleroderma	4.76e-05	0.000111	CcSEcCtD
Levofloxacin—Pruritus—Methotrexate—systemic scleroderma	4.74e-05	0.000111	CcSEcCtD
Levofloxacin—Diarrhoea—Methotrexate—systemic scleroderma	4.58e-05	0.000107	CcSEcCtD
Levofloxacin—Dizziness—Methotrexate—systemic scleroderma	4.43e-05	0.000103	CcSEcCtD
Levofloxacin—Vomiting—Methotrexate—systemic scleroderma	4.26e-05	9.95e-05	CcSEcCtD
Levofloxacin—Rash—Methotrexate—systemic scleroderma	4.22e-05	9.87e-05	CcSEcCtD
Levofloxacin—Dermatitis—Methotrexate—systemic scleroderma	4.22e-05	9.86e-05	CcSEcCtD
Levofloxacin—Headache—Methotrexate—systemic scleroderma	4.2e-05	9.8e-05	CcSEcCtD
Levofloxacin—Nausea—Methotrexate—systemic scleroderma	3.98e-05	9.3e-05	CcSEcCtD
